Menopause · Low libido · Updated May 2026
Estrogen decline reduces vaginal tissue health (atrophy, dryness, decreased blood flow) and contributes to reduced sexual desire centrally. Testosterone — produced primarily in ovaries and adrenals — also declines with age and further reduces libido.
Genitourinary syndrome of menopause (GSM) affects ~45% of postmenopausal women: dryness, dyspareunia, urinary urgency. GSM creates a pain-avoidance feedback loop that compounds libido issues.
Comorbid factors compound the problem: sleep disturbance, mood changes, body image shifts, relationship stress, and medication side effects (especially SSRIs/SNRIs).
Systemic estradiol improves vaginal health, mood, and energy — indirect benefits to libido. NAMS recommends transdermal estradiol + micronized progesterone for women < 60 without contraindications.
Estradiol cream, tablet (Vagifem), or ring (Estring) directly treats GSM. Minimal systemic absorption — safe in most patients with contraindications to systemic HRT (including some breast cancer survivors per ACOG guidance).
Compounded or transdermal testosterone (typically 1-2 mg daily — much lower than male dose). FDA has not approved testosterone for women, but Global Consensus Statement (2019) supports use for hypoactive sexual desire disorder with careful monitoring.
FDA-approved for premenopausal HSDD but used off-label in menopausal patients. Daily oral medication. Modest effect size (1 additional satisfying sexual event per month vs placebo).
FDA-approved on-demand subcutaneous injection for premenopausal HSDD. Used off-label in menopausal patients. Injected 45 minutes before anticipated sexual activity.
Comprehensive midlife women's health platform. Care team includes menopause-trained clinicians plus a community membership component.
Insurance-covered telehealth platform specializing in perimenopause and menopause care for women 35+.
Comprehensive hormone optimization for perimenopausal and menopausal women — bioidentical HRT with lab-driven dosing.
HRT improves vaginal health, mood, energy, and indirectly supports libido in many women. However, HRT alone often doesn't fully resolve hypoactive desire — testosterone supplementation, FDA-approved libido medications (flibanserin, bremelanotide), or couples therapy may be additionally needed.
Low-dose testosterone (1-2 mg/day, much lower than male doses) is considered safe with monitoring per the Global Consensus Statement (2019). Side effects include voice deepening, acne, and hirsutism at higher-than-recommended doses. Lipid and liver function monitoring is standard.
Vaginal estrogen restores tissue health, reduces dyspareunia, and breaks the pain-avoidance cycle that suppresses sexual interest. Many women report renewed libido after vaginal estrogen even though the medication has minimal systemic absorption.
Sildenafil (Viagra) is not FDA-approved for women. Trials in premenopausal HSDD showed minimal benefit. The FDA-approved female libido medications are flibanserin (Addyi, daily) and bremelanotide (Vyleesi, on-demand) — both indicated for premenopausal HSDD but used off-label in menopausal patients.
Not necessarily. With appropriate treatment (HRT, vaginal estrogen, addressing comorbid factors, and withometimes testosterone), most women see meaningful improvement in 3-6 months. Persistent issues may benefit from sex therapy in addition to hormonal treatment.